title: Deposition and effects of inhaled corticosteroids.
abstract: Inhaled corticosteroids are now recommended as maintenance therapy for all but the mildest cases of asthma, and may be delivered by a variety of devices and formulations. Drug delivery may be assessed by both in vitro and in vivo methods. Although drug deposition in the lungs is expected to predict clinical response, this relationship is often masked by the flat nature of corticosteroid dose-response curves. The effects of inhaled corticosteroids depend not only upon the pharmacology of the drug being administered, but also upon its delivery system, with more efficient devices not only improving therapeutic effect but also potentially increasing systemic adverse effects. Modern delivery systems that enhance drug targeting to the lungs make it possible to use lower dosages of inhaled corticosteroid, such that the clinical response is maintained but systemic exposure reduced.
authors.affiliation: Pharmaceutical Profiles Ltd, Ruddington, Nottingham, UK. steve.newman@pharmprofiles.co.uk
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Newman
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000335:Aerosol Propellants; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D011877:Radionuclide Imaging
chemical_list: D000305:Adrenal Cortex Hormones; D000335:Aerosol Propellants; D018927:Anti-Asthmatic Agents